Oncology Rehabilitation: Evidence‑Based Physiotherapy CPD for Cancer Care

Oncology Rehabilitation: Evidence‑Based Physiotherapy CPD for Cancer Care

10.00 USD In stock Buy at Merchant

This CPD course equips physiotherapists and rehabilitation professionals with practical, evidence‑based tools for oncology care. Develop confidence in managing cancer‑related fatigue, pain, deconditioning, neuropathy, and post‑treatment functional decline. Its also suited for clinicians working in acute oncology, outpatient rehabilitation, community services, palliative care, and private practice, and is ideal for those seeking to enhance their clinical decision‑making, therapeutic planning, and evidence‑based practice within oncology physiotherapy. Participants will learn to identify: Capability to design, justify, and progress rehabilitation programmes Mobility, endurance, balance Overall quality of life for oncology patients at varying stages of treatment and survivorship. Course Objectives Define the role of specialised physiotherapy in comprehensive oncology care. Identify systemic side effects of cancer treatment managed by movement strategies. Explain evidence-based strategies for managing cancer-related fatigue and other side effects. Outline a patient-centric, personalised approach to management and intervention. Duration: 1 Hour Who can enrol: PT PTA COTA Cancer nurses Rehabilitation Therapists Author: Dr Rina Pandya, PT, DPT, FHEA, PGLTHE. This CPD course equips physiotherapists and rehabilitation professionals with practical, evidence‑based tools for oncology care. Develop confidence in managing cancer‑related fatigue, pain, deconditioning, neuropathy, and post‑treatment functional decline. Its also suited for clinicians working in acute oncology, outpatient rehabilitation, community services, palliative care, and private practice, and is ideal for those seeking to enhance their clinical decision‑making, therapeutic planning, and evidence‑based practice within oncology physiotherapy.

AI Readiness

Good foundation, but some important product data is still missing.

66%